Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

LGND

Peringkat dalam Saham #3109
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Harga Saham
$291.18
Terakhir disinkronkan: 2026-07-31
Kapitalisasi Pasar
$5.84B
Perubahan (1 hari)
-1.73%
Perubahan (1 tahun)
55.99%
Negara
US
Perdagangan Ligand Pharmaceuticals Incorporated (LGND)

Kategori

Healthcare
Riwayat pemecahan saham untuk Ligand Pharmaceuticals Incorporated (LGND)
Saham Ligand Pharmaceuticals Incorporated (simbol: LGND) telah mengalami total 2 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Nov 02, 2022.
Satu lembar saham LGND yang dibeli sebelum Nov 19, 2010 sekarang setara dengan 0.26716666666667 lembar saham LGND.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
2022-11-02 1603:1000 x1.603 x0.26716666666667
2010-11-19 1:6 x0.16666666666667 x0.16666666666667
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL